Rational Vaccines (RVx) is developing a new line of prophylactic HSV vaccines
Rational Vaccines (RVx) is developing a new line of prophylactic HSV vaccines, ProfavaxHSV-1 and ProfavaxHSV-2, that are based on live-attenuated HSV ICP0– mutant viruses, and which may be used to safely vaccinate recipients with >99% of HSV’s foreign protein signature. ProfavaxHSV-1 and ProfavaxHSV-2 offer an opportunity for the global eradication of most, if not all, forms of herpetic disease.
In the absence of an effective HSV vaccine, everyone in the world is either infected with HSV-1 and/or HSV-2 or is susceptible to being infected by these viruses. This creates a condition where there are no barriers to the ongoing epidemic spread of HSV-1 and HSV-2 to over one million people per week.
ProfavaxHSV-1 and ProfavaxHSV-2 offer an opportunity for the global eradication of most, if not all, forms of herpetic disease.
The full power of a prophylactic vaccination program built upon ProfavaxHSV-1 and ProfavaxHSV-2 lies in “herd immunity.” By vaccinating individuals with Profavax before they are exposed to disease-causing strains of HSV-1 or HSV-2, we may reduce their risk of contracting herpetic disease and transmitting it to others.
This long-term vision will require governments to implement vaccination programs. In the interim, RVx is committed to offering immediate solutions to help reduce or eliminate the risk of HSV transmission within HSV discordant couples via prophylactic vaccination. Learn more about how ProfavaxHSV vaccines will help solve the world’s herpes problem.